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Cost-effectiveness and diagnostic accuracy of
telemedicine in macular disease and diabetic
retinopathy
A systematic review and meta-analysis
Waqas Ullah, MDa,
∗
, Sana Khan Pathan, MDb, Ankur Panchal, MDc, Swapna Anandan, MDb,
Kaiser Saleem, MDb, Yasar Sattar, MDd, Ejaz Ahmad, MDe, Maryam Mukhtar, MDf, Haq Nawaz, MDb
Abstract
Objective: To determine cost-effectiveness and the diagnostic accuracy of teleophthalmology (TO) in the detection of macular
edema (ME) and various grades of diabetic retinopathy (DR).
Methods:MEDLINE, EMBASE, and Cochrane databases were searched for TO, ME, and DR on May 25, 2016. The search was
updated on April 2, 2019. Pooled sensitivity and specificity for ME and various grades of DR were determined using Meta-Disc
software. A systematic review of the articles discussing the cost-effectiveness of TO screening was also performed.
Results: Thirty-three articles on the diagnostic accuracy and 28 articles on the cost-effectiveness were selected.
Conclusions: Telescreening is moderately sensitive but very specific for the diagnosis of diabetic retinopathy. Non-mydriatic
Teleretinal screening services are cost-effective, decrease clinics workload, and increase patient compliance if provided free of cost in
remote low socioeconomic regions.
Abbreviations: CSME= clinically significant macular edema, DME= diabetic macular edema, DoD=Department of Defense, DR
= diabetic retinopathy, ETDRS = Early Treatment Diabetic Retinopathy Screening, IHS = Indian Health Service, JVN = Joslin Vision
Network, ME = macular edema, NPDR = non-diabetic proliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy,
QALY = quality-adjusted life-year, TO = teleophthalmology, VA = Department of Veterans Affairs.
Keywords: diabetic retinopathy, macular edema, teleophthalmology
1. Introduction
Recent surveys indicate that approximately 382 million of the
world population and 29.1 million of the US population has
diabetes mellitus.[1,2] If no action has been taken, this number will
double by 2035.[1] With such a significant portion of the
population affected by diabetes, managing complications of this
disease are paramount. The most common complication of
diabetes is diabetic retinopathy (DR), affecting about 28% of the
diabetic population.[3] According to WHO, DR accounts for
almost 17% of all cases of blindness in the USA and Europe,
and the number of Americans with DR will nearly double from
7.7 million to 14.6 million by the end of 2050.[4] Good glycemic
control, early diagnosis, and prompt management of DR can
delay the progression of DR into blindness.[5] Despite this
knowledge, only about 55% of the diabetic patients in the United
States receive retinopathy screening.[6] Similarly, the systematic
implementation of DR testing is not common in many low and
middle-income countries.[5,7] The main reasons responsible for
the poor compliance to the DR screening are high testing
expenses, inadequate health care facilities, and limited access to
conventional screening strategies.[8] Teleophthalmology recently
has gained particular importance as an alternative screening
method to overcome the barriers in the face of DR screening.[9]
Teleretinal technology is believed to improve access and reduce
the cost of the DR and ME screening. However, the diagnostic
accuracy and cost of this screening modality depend on many
variables including the use of pupillary mydriasis, an instrument
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used, the qualifications of the photographer, number of
photographic fields, and the image interpreter. Many studies
have been done to discuss the utility of this technology, but the
literature on the cost-effectiveness and diagnostic accuracy of
Teleretinal screening are yet limited. We present the results of a
systematic review and meta-analysis of studies evaluating the
cost-effectiveness and pooled sensitivity and specificity of TO in
DR and ME screening.
2. Methods
2.1. Search strategy and selection criteria
The initial literature search for relevant articles was performed on
May 25, 2016, using MEDLINE (PubMed, Ovid), Embase, and
Cochrane databases. The search was updated on April 2, 2019.
There was no language or time restriction placed on the search.
The search strategies included various combinations of text-
words andmedical subject headings (MeSH) to generate 2 subsets
of citations: one for ME or DR, using the MeSH and terms like
“macular edema,” “diabetic retinopathy,” “diabetic maculop-
athy,” “diabetic macular edema,” “diabetic ophthalmopathy,”
“diabetic eye disease,” and “diabetic ocular disease” and the
other for teleophthalmology using terms and MeSH like
“telemedicine,” “telehealth,” “mhealth,” “ehealth,” “medical
informatics,” “clinical decision support system,” “computer-
assisted decision making,” “information system,” “teleophthal-
mology diabetes,” “tele maculopathy diabetes,” “tele health-
care,” “mobile health,” “health information technology,”
“software-assisted analysis.” The terms from the 2 subsets were
combined in 1:1 combination and finally results from all the
possible combinations were downloaded into an EndNote
library. Based on our research question, we also manually
searched the references in all known articles to identify studies
that were missed by the initial search. An ethics approval was
obtained from the institutional review board (IRB) for this study.
The selection criteria for the included studies were: recruited
subjects with macular edema or diabetes mellitus either type 1 or
type 2, discussed the cost-effectiveness or cost-utility of tele-
ophthalmology screening, provided data on the sensitivity or
specificity of Teleretinal screening. Studies with insufficient data,
discussing only the prevalence of diabetes, case reports, and
conference papers were excluded, as studies with no enough
description of its subjects.
2.2. Study selection
The titles and abstracts of the selected articles were reviewed
independently by 3 authors and the articles which met the
inclusion criteria were reviewed by the fourth author. Full-text
articles that were potentially relevant to the study were also
reviewed by all the 4 authors to confirm the eligibility.
Disagreements were resolved by mutual consensus and after a
detailed group discussion.
2.3. Data abstraction and analysis
Two reviewers extracted data on the study characteristics, cost-
effectiveness, and sensitivity and specificity of Teleretinal
screening. Disagreements were resolved by consensus and by a
discussion with a third reviewer. After carefully assessing the
extracted data, pooled sensitivity and specificity were calculated
using the Meta-Disc software, RevMan Version 5.3, London,
United Kingdom.
2.4. Quality assessment
The quality assessment of all the included articles studies was
performed using the RevMan 5.3. Selection, detection, attrition,
and reporting bias for all studies was assessed.
3. Results
The combined systematic search strategy identified a total of
3814 articles. After excluding 1201 duplicate items, the
remaining 2613 pieces of literature were screened for relevance
based on their titles and abstracts, and 2183 articles were further
excluded. A total of 430 were deemed potentially eligible and
retrieved for a full review. After a detailed review, a total of 369
articles were further excluded for the following reasons: screening
strategies other than teleophthalmology (n=145), telemedicine
services of diabetic care (n=27), cost of diabetic care (n=26),
telemedicine for treatment of DR (n=48), diabetes prevalence
and management (n=62), telerehabilitation of diabetics (n=18),
telemedicine on visual acuity and retinitis pigmentosa (n=9), and
articles on Teleretinal diabetic prevalence (31). Thirty-three
articles on the diagnostic accuracy and 28 articles on the cost-
effectiveness were included.
Figure 1 presents a Preferred Reporting Item for Systematic
Reviews and Meta-analysis (PRISMA) flowchart of the study
selection process along with reasons for study exclusion.
3.1. Summary characteristics of the included studies for
diagnostic accuracy
A total of 33 studies were selected for the analysis. All these
studies used Teleretinal screening either alone or in comparison
to other screening modalities like ophthalmoscopy, slit-lamp
examination, or 7-field Early Treatment Diabetic Retinopathy
Screening (ETDRS). Both men and women with either type 1 or
type 2 studies were included in the recruited studies, except
Hubbard et al[10] study which included patients with type 1 DM
only. More than 10,000 people from 8 different countries were
screened in all the studies. Almost 80% of the total studies were
conducted in the UK, Canada, and at various states of the United
States. In >50% of the included studies, digital imaging was
carried out with mydriasis except for Hansen et al[11] and
Lawrence[12] study in which both mydriatic and non-mydriatic
images were obtained. Images were transferred through a secure
web browser, telemetrically, or via an online network.[13–16] A
description of the included studies for diagnostic accuracy is
presented in Table 1.
4. Discussion
4.1. Diagnostic accuracy
The cumulative diagnostic accuracy of teleophthalmology for
diabetic macular edema (DME) showed a mean sensitivity of
59% with a range as <30% and a maximum value of 88%.
While specificity ranged from 82% to 98% with a mean of 93%
and a standard deviation of about 6%. While for clinically
significant macular edema (CSME) these values were 38% and
100%, respectively. The mean for CSME was 66%, the standard
Ullah et al. Medicine (2020) 99:25 Medicine
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deviations for both were 26% and 22%, respectively. The
specificity ranged from 75% to 100%with a mean of 94% and a
standard deviation of about 8%.
Teleophthalmology was found to be 87% sensitive and 91%
specific for the absence of retinopathy. For mild non-diabetic
proliferative diabetic retinopathy (NPDR), the total number of
articles was 16, with a minimum value of sensitivity 35% and a
maximum value of 93% with a mean of 74% and the standard
deviation was 0.16481. The mean specificity ranged from none to
98% with a mean of 50% and the standard deviation was 44%.
The sensitivity of moderate NPDR was reported in 15 articles
having a minimum to maximum range 32% to 100% with a
mean and standard deviation of 71% and 19% respectively.
These values for specificity ranged from none to 98% with a
mean and standard deviation of only 48% and 47% respectively.
For severe NPDR, the mean sensitivity was 42% with a standard
deviation of 27% and a range from none to 79%. Surprisingly the
specificity of telemedicine was very high ranging from 94% to
100% and amean of 94%having only 1%of standard deviation.
As far as individuals with low risk proliferative diabetic
retinopathy (PDR) were concerned, the teleophthalmology was
found to 75% sensitive with respect to the gold standard
ophthalmoscopy with a range from 0% to 100% among different
studies. These values were ironically high for mean specificity that
was 98% ranging from 94% to 100% among individual studies
having a negligible standard deviation of only 2%. Lastly, for
high-risk PDR, the minimum sensitivity value of 0.00 and a
maximum value of 100% were found among studies while the
mean sensitivity was 76% and the standard deviation was 31%.
The specificity ranged from 69% to 100% and the mean and the
standard deviation was 94% and 9% respectively. The individual
sensitivities and specificities of the included studies are tabulated
in supplementary table S1, http://links.lww.com/MD/E387.
4.2. Quality assessment of included studies
The detailed quality assessment and risk of bias assessment of the
included studies are summarized in supplementary table S2,
http://links.lww.com/MD/E388 and shown in Fig. 2 below. The
detailed summary of bias assessment is shown in supplementary
figure S1, http://links.lww.com/MD/E384. Overall the quality of
the studies included in our meta-analysis was high. The allocation
concealment might have introduced a high risk of selection bias in
the Hansen study.[11] Silva performed 2 similar studies in 2012
and the risk of bias assessment could be done only on one study
while the second study had insufficient information. Selection
criteria were well defined in almost all studies. Chances for
detection bias and attrition bias were low as there not enough
unblinded studies or studies reporting incomplete data respec-
tively. Due to complete reporting of outcomes in all studies, the
reporting bias was minimal in all studies.
4.3. Cost-effectiveness
Cost-effective Teleretinal screening programs have been reported
in many clinical settings, including Canada, India, United States,
Norway, and the United Kingdom.[42–60] A total of 28 studies
were identified assessing the cost-effectiveness of teleophthalmol-
Figure 1. PRISMA flow sheet of the selected studies.
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Figure 2. Quality assessment of the included studies shows inclusion of well conducted studies.
Table 1















1 Massin et al, 2005, France [17] 74/147 52/25–74 8/0–23 5, 45, non-stereoscopic, color, No 1490960
2 Hansen et al, 2004 [11] 83/165 47/25–70 22/1–53 5, 45, non-stereoscopic, color, both 14501026
3 Schiffman et al, 2005 [18] 111/222 57/18–99 19/1–49 15, 55–60, non-stereoscopic, color, no N/A
4 Gangaputra et al, 2011 [19] 96/157 62/37–86 19/NA 4–7, 30–60, stereoscopic, color, yes N/A
5 Hubbard et al, 2011 [10] 319/628 48/NA 27.2/NA 7, 30, stereoscopic, color, yes N/A
6 Kernt et al, 2011 [13] 34/66 62/NA 14.3/NA 1200, non-stereoscopic, color, yes N/A
7 Maker et al, 2012 [20] 106/211 49/19–78 23.7/NA 7, 30, stereoscopic, color, yes 12801024
8 Silva et al, 2012 [21] 3864/7728 53/NA 12–13/NA 1100 and 200, stereoscopic, color, no 10001000
9 Kernt et al, 2012 [14] 141/212 64/25–78 12/3–39 1180–200, non-stereoscopic, color, no 39003072
10 Tennant et al, 2000, Canada [22] 121/241 57/9.0–83 8.5/NA 7, 30, stereoscopic, yes 20083040
11 Gomez-Ulla et al, 2002, Spain [23] 70/126 N/A/NA NA N/A, 35–45, N/A, no N/A
12 Harding et al, 1995, UK [24] 395/NA 60.2/NA NA 3, 45, non-stereoscopic, yes NA
13 Li et al, 2010, US [25] 85/152 59/33–83 NA 9, 45, monoscopic, color, yes 2400/30002000
14 Silva et al, 2012, US [26] 126/67 49/24–83 21.1/(1–51) 3 field 45°, 2 field 30°, stereoscopic, no 12001600
15 Cavallerano et al, 2012, US [27] 158 /316 56/22–86 7.0/(0.1–42) NA, 35, stereoscopic, no N/A
16 Torok et al, 2015, Hungary [28] 52/104 65.2/NA 16.4/NA 7, N/A, N/A, No N/A
17 Ting et al, 2012, Aus [29] 136/272 53.9/NA 13.9 /NA 3, 35, non-stereoscopic, yes N/A
18 Usher et al, 2004, UK [30] 1273/NA N/A/NA N/A NA, 45, N/A, N/A, yes 570570
19 Bursell et al, 2001, US [31] 54/108 48/20–75 17.7/3–42 3, 45°, stereoscopic, no 640480.
20 Russo, et al, 2015, Italy [32] 120/240 58.8/NA 11.6/6–9.7 N/A, 20, NA, N/A, yes N/A
21 Pirbhai et al, 2005, UK [33] 118/223 79.2/NA N/A N/A, N/A, N/A, yes 10241024
22 Peter et al, 2006, Aus [34] N/A/NA N/A/NA N/A Four different fields, 60/45/30, N/A, yes N/A
23 Rudnisky et al, 2007, Canada [15] 102/204 57/18–99 1 m–35 yr 7, 30, stereoscopic (field1, 3)
non-stereoscopic (field3, 7), color, yes
30402008
24 Cook et al, 2014, UK [35] N/A/NA N/A/NA N/A N/A, N/A, N/A, N/A N/A
25 Lin et al, 2002, US [16] 197/NA NA/21–80 N/A 1, 45°, stereoscopic, no 640480
26 Rajalakshmi et al, 2015, India [36] 301/602 53/43–63 12.5±7.3 4, 45, N/A, N/A, yes N/A
27 Boucher et al, 2003,Canada [37] 98/196 59/26–92 N/A 2, 45, non stereoscopic, color,no 1024768
28 Andonegui et al, 2010, Spain [38] 1223 N/A N/A N/A N/A
29 Lawrence, 2004, US [12] N/A 67.5 12.4/0–58 N/A,45, non-stereoscopic, color, both 640480
30 Alessandro [39] 1281 65.69±12.64 years 1 3, 30,N/A, yes N/A
31 Rodríguez [40] 394 N/A 5 N/A N/A
32 Pritam [41] 564/1128 53 (20–85) 5 7, N/A, stereoscopic, color, yes N/A
33 Sasso FC [72] 1907/3814 66/57–72 8 N/A N/A
Ullah et al. Medicine (2020) 99:25 Medicine
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Table 2





characteristics Screening modalities Screening outcomes Economic outcomes
1 Bjorvig et al, 2002, Norway [42] 250,42 diabetic patients Conventional evaluation by
ophthalmologist vs digital
images transmitted via email
Cost comparisons depending
on volume of screening
At higher workloads, telemedicine led
to lower costs; at 200 patients
per year, telemedicine cost $164
per patient and conventional
examinations cost $243.5 per
patient
2 Maberley et al, 2003, Canada [43] 650 Visits every 6 months by retina
specialists vs photographic
screening with a digital
camera
Costs per sight-year saved
and costs per QALY
The camera program was more cost-
effective, and had the best cost-
per- QALY ratio, at $15,000; the
camera program would cost
<$5000 per year of vision saved
if 65% or more of the population
was screened
3 Aoki et al, 2004, US [44] 10,000 Non Mydriatic retinal camera TO
vs conventional evaluation by
eye care provider
QALYs gained and costs
generated
Average CE was $882 per QALY for
TO and $947 for non-TO; in the
TO strategy, 12.4% of patients
reached blindness versus 20.5%
in non-TO; ARR for blindness:
8.1%, NNS by TO to prevent a
blindness case: 12.4%
4 Whited et al, 2005, US [45] Large cohort from IHS,
VA, and DoD data
Clinic based ophthalmoscopy
with pupil dilation vs JVN
digital TO system (JVN)
Number of true positive
cases of proliferative DR
detected
Number of additional cases and
savings with JVN: IHS: 148 cases
and $525 690; VA: 96 PDR
cases and $2 966 111; DoD:
165 and $129,046; JVN provides
better outcomes at lower costs
than clinic-based ophthalmoscopy
in most scenarios






cost less than conventional
examinations ($49.95 vs $77.80)
6 Rachapelle et al, 2013, India [47] 1000 Mobile van, optometrist takes 4
dilated stereoscopic 45° fields
digital retinal photographs with
non mydriatic camera
QALY gained from TO vs no
screening, CU at different
intervals
Rural TO was cost- effective ($1320
per QALY) compared with no
screening; screening intervals of up
to every 2 years also were cost-
effective, but annual screening was
not ($3183 per QALY)
7 Kirkizlar et al, 2013, US[48] 900, T1D and T2D TO vs regular office visits and
evaluation by ophthalmologist
DR, ME, blindness, and
associated QALYs
TO is CE in most conditions;
telemedicine screening is not CE
in patients aged older than 80
years or in populations with
>3500 patients
8 Phan et al, 2014, US [49] 1793 diabetic patients Topcon digital retinal cameras,
non mydriatic imaging
Cost of teleretinal screening Teleretinal screening was associated
with cost reduction to health plan
payers (average cost reduction per
screen of $24.38) and a decrease
in eye clinic physician workload
but failed to match the investment
cost (53% gained back by study
end)
9 Brady et al, 2014, US [50] 99 (base case),
100,000 trials (Monte
Carlo simulation)
3-field non mydriatic fundus
photography; images were
transmitted to a remote expert
reader
Estimation of costs of
screening for PDR
TO screening for PDR resulted in
savings of $36 per patient (base
case), and a median of $48 in the
simulation model
10 Maamari et al 2013 [51] N/A 55°, non mydriatic image Cost of the camera Ocular CellScope $883.22
11 Taylor et al 1999 [52] ∗197∗∗534 45°, mydriatic image vs 7 field
stereo photography
Cost of the number of
images
For this reason, although multiple
photography is a good idea, it is
costly with 35mm photos
approximately £0.30 each and
Polaroids £1 each; costs which
are increasing.
(continued )








characteristics Screening modalities Screening outcomes Economic outcomes
12 Taylor et al 2000 [53] 64,905 people screened TO vs no screening program Number of true positive
cases of proliferative DR
detected
The average cost of screening was
f13.1 1 per patient and the
average cost of identifying a
person requiring laser therapy was
f1110.
13 Davis et al [54] 165; 85 TO vs no screening program Usual care, transportation
and equipment costs
Usual care; staff time and fringe
benefits $12. Transportation $19,
supplies and incentives $1: total
$32 DTC intervention; staff time
and fringe benefits $802.
Transportation $217 telemedicine
equipment $225 teaching aids
$45 supplies and incentives $99
mailing and shipping $25 total
$1413 screening eye exam; staff
time and fringe benefits $20
equipment and supplies $266
total $286
14 Invernizzi et al 2015, Italy [55] 1281 3-field, 30° images vs slit-lamp
funduscopic examination
Cost of image generation For the remote reading of images,
the cost was calculated at €2.50
per reading. The cost of image
generation plus reading was
therefore €4.45 per patient.
15 Lawrenson et al 1995 [56] 396 50 degree mydriatic images Usual care and equipment
costs
Nurse $3 photographer $5 travel and
accommodation $3 film $5
ophthalmologist $3 administration
$2 total $21 camera cost
$22,200 carrying case $1100
frame for station wagon $1350
total 24,650 $ depreciated over 5
years at $5000 per annum




Self-referral resulted in average per
person ophthalmologic-related
costs of US $7,368, telemedicine
increased costs by US $3,343,
biennial evaluation by US $3636,
and annual evaluation by US
$4809
17 Leese et al, 1993, UK [58] 2,984/5,968 TO vs no screening program Cost per patient screened The screening programme in Tayside
cost £10 per patient screened
18 Bjørvig et al, 2002 [59] 20–200 TO vs no screening program Cost comparisons depending
on volume of screening
The total cost of examination by
conventional methods was
NKr8555 at a workload of 20
patients per annum and
NKr288,040 at 200 patients per
annum. In comparison, the total
cost of telemedicine examination
was NKr171,102 and NKr194,169
at the same respective workloads
19 Müller et al, 2006, AUS [60] 1695 TO vs no screening program Usual care and equipment
costs
Total study expenditure, including





Screening cost per participant was
only about AU$145, compared
with AU$433 in the VIP.
(continued )








characteristics Screening modalities Screening outcomes Economic outcomes
20 Thompson et al 1995, UK [61] 4312 eyes TO vs no screening program Cost comparisons depending
on clinical screening
settings
The cost of diagnosis per true
positive case of sight-threatening
retinopathy ranged from £633 to
£ 1079 for general practitioners,
£497 for a mobile community-
based retinal camera, £1546 for a
hospital based retinal camera,
£1028 for opticians and £1033
for hospital physicians.
21 Brown-Connolly et al 2014 [62] 5219∗, 6426∗∗ ∗Non-mydriatic images vs
∗∗Biometric Screening
Vision screening for adults >65
years old 650,17 vs $1,202,906
22 Sculpher et al, 1992, UK [63] 3423 diabetic patients Evaluation of 13 screening
options
Cost of different modalities,
expected cost per true
positive case detected
Cost savings can result with
systematic screening during the
same appointment as other
routine health checks, compared
to screening requiring additional
visits




Sight-threatening eye disease The CE was £209 and £289 for
systematic and opportunistic
screening, respectively, and
incremental CE was £32 for each
additional case; systematic
screening remained more cost-
effective than opportunistic
screening
24 Facey et al, 2002, Scotland [65] 2000 iterations through
Crystal Ball
Conducted by optometrists,
hospitals and GPs at any
opportunity vs a systematic
health authority program,
primarily by digital camera
(mydriatic and non mydriatic
screening)
Cost per QALY for the move
from one screening
program to another
The most cost-effective modality:
combination of single staffed
hospital units and mobile vans
using non mydriatic digital
photography
25 Tu et al, 2004, England [66] 769 optometric screen
and 874 digital photo-
graphy
Topcon non mydriatic model
(professional medical




CE for optometry= total cost/true
positives=£18,454/22=£839;
cost per patient screened=
£25,599.30/874=£29.29; CE for
digital photography=£25,599/
30=£853; CE was poor in both
models
26 Khan et al, 2013, South Africa [67] 14,541, primary care,
T2D
Mobile non mydriatic digital
camera (photographs taken by
a trained technician with
supervision by an ophthalmic
nurse)
Cost per blindness case
averted
Non Mydriatic fundus photography is
cost-effective; the cost of DR
screening was $22 per person;
ICER was $1206 per blindness
case averted
27 Lian et al, 2013, Hong Kong [68] 2766 diabetic patients Non Mydriatic fundus camera
(optometrist); subsequently
graded by optometrist and
ophthalmologists
Uptake of screening and
severity of DR detected
Lower screening (OR, 0.59; CI,
0.47–0.74) and a lower detection
rate of DR (OR, 0.73; CI, 0.60–
0.90) in the pay group
28 Kawasaki et al, 2014, Japan [69] 50,000 hypothetical
cohort
Incidental diagnosis, non
mydriatic 45° photograph in





Rate of detecting DR,
preventing blindness, and
costs of DR management
DR screening program in Japan is
cost-effective compared to the no
systematic screening; blindness
reduction of ∼16%; incremental
cost of $64.6, and incremental
effectiveness of 0.0054 QALYs
per person screened; ICER was
$11,857 per QALY
AA=African American, ARR= absolute risk reduction, CE= cost effectiveness, CI=confidence interval, CU= cost-utility, DoD=Department of Defense, DR=diabetic retinopathy, GP=general practitioner,
ICER= incremental cost-effectiveness ratio, IHS= Indian Health Service, JVN= Joslin Vision Network, ME=macular edema, Nkr=Norwegian Krone, NNS=number needed to screen, NP=nurse practitioner,
OCT= optical coherence tomography, OR=odds ratio, PA=physician assistant, PDR=proliferative diabetic retinopathy, QALY=quality-adjusted life-year, T1D= type 1 diabetes, T2D= type 2 diabetes, TO=
teleophthalmology, VA=Department of Veterans Affairs.
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ogy screening of DR and ME in these clinical settings. The cost
analysis was done based on delivery modalities (e.g., telemedi-
cine, clinic camera), screening models like systematic screening
versus opportunistic and screening outcomes such as Quality-
Adjusted Life-Year (QALY), cost per true positive case detection,
DR severity, screening intervals, population, and referral
duration (Table 2).
Populations screened at a younger age, higher HbA1c, using
insulin, or with high transportation costs derive most of the
benefit from Teleretinal screening.[44,48] Besides, disease burden
and population size determine the cost-effectiveness of a
Teleretinal screening program. Compared with conventional
screening, Teleretinal screening was cost-effective at a high
workload. A saving of 74$ and NKr 28,7186 per patient was
noticed in a population of 200 patients per year.[42,59] At lower
workload of 20 patients, the cost-saving for Teleretinal screening
was only about NKr 8384 with respect to the conventional
screening.[59] However, teleophthalmology (TO) was not
economic in patients >80 years of age and in population
>3500 patients, similarly multiple photographies with 35mm
photos cost approximately £0.30 extra for each image.[48,52]
Furthermore, in many studies, non-mydriatic screening
approaches perform well and were cost-effective compared with
mydriatic use.[43,65,45,46,67]
Subjects with a high socioeconomic condition or those living in
better areas were screened more often but were less likely to have
DR detected, suggesting the importance of access to screening.[68]
Free screening was associated with a higher compliance rate,
higher chances of DR detection, and a decreased workload on
clinic physicians.Multiple studies discussed the approximate cost
of the usual care like supplies and incentives, transportation
charges, staff time, and fringe benefits (19$–32$).[54,56,60] The
per-patient cost of screening was estimated to be 24$ to 36
$.[49,50] If telemedicine equipment and teaching aids were added
the approximate screening cost per participant was about AUS
$145 per visit and about 5000 US $ per annum.[54,56,60] The
systematic screening model was more cost-effective than the
opportunistic screening model in many studies. James et al[64]
showed that the cost was £209 and £289 for systematic and
opportunistic screening, respectively.
Screening interval is also an important factor in determining
the cost-effectiveness of Teleretinal screening in asymptomatic
patients screening every 2 years can save 900 to 1863 US $ than
annual screening.[47,57] Whited et al[45] compared clinic-based
ophthalmoscopy to teleretinal screening at Joslin VisionNetwork
(JVN) to determine the true positive case detection cost. In Indian
Health Service (IHS) 148 cases saved $525,690, in the
Department of Veterans Affairs (VA) 96 PDR cases saved
$2,966,111 while in the Department of Defense (DoD) 165 cases
saved $129,046, concluding that JVN provides better outcomes
at lower costs than clinic-based ophthalmoscopy in most
scenarios. Tu et al[66] in his study showed that true positive
detection cost of DR on digital photography by TO was
significantly lower (£839) than slit-lamp detection cost of DR
(£853) and cost per patient screened was as little as £29.29 per
patient.
5. Limitations
Our study did not focus on the prevalence of telemedicine and
telescreening in developing countries.
Teleretinal screening would offer more benefits in developing
and underdeveloped countries. A population-based survey in
Nakuru, Kenya revealed that the prevalence of any type of DR
was 35.9% and of severe non-proliferative DR was 13.9%.[70]
Similarly, within Asia-Pacific India has a 10% prevalence of DR
while Indonesia has a prevalence of 43% for DR. We believe that
such developing countries would benefit more from a teleretinal
screening program.[71,72]
6. Conclusion
Teleophthalmology is very sensitive and specific for the absence
of retinopathy but for the diseased retina, these values have
widespread variations. It is highly specific for DME, CSME, PDR,
and severe NPDR but non-specific for mild or moderate NPDR.
The sensitivity of all kind of retinopathies was not impressive.
However, the relatively small cost of Teleretinal screening makes
for an attractive platform for both image acquisition, storage,
interpretation, and transmission. In contrast to clinical examina-
tion and conventional screening, Teleretinal screening reduces the
burden in the eye clinic and improves access in remote
environments. Moreover, screening a small number of individu-
als is not economically sound, and a larger population screening
with the omission of pupillary mydriasis can be more cost-
effective. Telescreening also increases screening compliance and
prevent blindness in a high number of a population if the services
are offered free of cost.
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